Drug Combination Details
| General Information of the Combination (ID: C61153) | |||||
|---|---|---|---|---|---|
| Name | Silibinin NP Info | + | Regorafenib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | EIF4EBP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SW48 | CVCL_1724 | Colon adenocarcinoma | Homo sapiens | ||
| GEO | CVCL_0271 | Colon carcinoma | Homo sapiens | |||
| LIM1215 | CVCL_2574 | Colon adenocarcinoma | Homo sapiens | |||
| HCT 15 | CVCL_0292 | Colon adenocarcinoma | Homo sapiens | |||
| HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | |||
| SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | |||
| LoVo | CVCL_0399 | Colon adenocarcinoma | Homo sapiens | |||
| SW620 | CVCL_0547 | Colon adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
The combined treatment with regorafenib and silybin induced synergistic anti-proliferative and apoptotic effects by blocking PI3K/AKT/mTOR intracellular pathway. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. Oncotarget. 2017 Aug 7;8(40):68305-68316. | |||
